KLRS

Kalaris Therapeutics, Inc.

NASDAQ: KLRS · HEALTHCARE · BIOTECHNOLOGY

$5.22

+1.51% today

Updated 2026-06-03

Market cap

$105.64M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.78

Dividend yield

—

52W range

$2 – $12

Volume

0.1M

Market cap

$105.64M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.78

Dividend yield

—

52W range

$2 – $12

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-0.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$18.75

+259.20%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.02x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -0.91 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-13.35M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-15.48M	$-14.70M	$-58.77M	$-43.44M	$-10.86M
EPS	—	—	—	—	$-0.78
Free cash flow	$-9.78M	$-14.13M	$-67.70M	$-43.18M	$-13.35M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
KLRS	$105.64M	29	4.3	3.0	5.0	6.5	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Kalaris Therapeutics, Inc. trades at $5.22. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -0.91, it sits in the distress.

Frequently asked questions

What is Kalaris Therapeutics, Inc.'s stock price?

Kalaris Therapeutics, Inc. (KLRS) trades at $5.22.

Is Kalaris Therapeutics, Inc. overvalued?

Kalaris Therapeutics, Inc. carries a Smart Value Score of 29/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Kalaris Therapeutics, Inc. (KLRS)?

The 12-month analyst consensus target is $18.75, about 259.2% above the current $5.22. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Kalaris Therapeutics, Inc.'s Altman Z-Score is -0.91, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

kalaristx.com

Quick metrics

P/S ratio—

ROE-64.32%

Beta—

50D MA$5.57

200D MA$6.60

Shares out0.02B

Float0.01B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

KLRS vs LLY →KLRS vs JNJ →KLRS vs ABBV →Stock screener →